This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...